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INTRODUCTION 
 
Of all gynecologic cancers, ovarian  malignancies  represent  the 
greatest clinical  challenge. Epithelial ovarian malignancies  are the most 
common type of ovarian malignancy. Epithelial Ovarian Cancers (EOC) 
can occur in females as young as 15 years, but the mean age is 56 years. 
Epithelial Ovarian cancers (EOC) are the most commonly in white women 
in the industrialized countries of northern and western  
 Europe and North America and least commonly in India and Asia. 
 
Patients have advanced disease at diagnosis in more than two- thirds 
of the cases. It has the highest fatality-to-case ratio of all the gynaecologic 
malignancies.  
 
EOC is responsible for 2% all cancers and 2.9 %  cancer deaths. 
 
 Incidence:  0.7/1 lakh women at 20 years 5/1lakh women at 40 
   years  30-40/1lakh women at > 60 years. 
   The incidence of EOC is highest in the   
   Scandinavian countries.  22.2%. 
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From ICMR & IARC. Lit. 
 
Switzerland      16.3 
UK                    12.4 
Delhi                  10.2 
Mumbai              8.8 
Trivandram          6.3 
Bhopal                 5.7 
Chennai               5.3 
Bangalore            5.1 
Japan                   2.7 
US (Native Whites)   0.5 
US (Native Blacks)     0.1 
 
Rate 1/1, 00, 000 
Pathology 
EOC tumors are found as partially cystic lesions with solid components. 
The surface may be smooth or covered in papillary projections and the 
cysts contain fluid ranging from straw-colored to opaque brown or 
hemorrhagic. EOC is thought to arise from epithelium covering the 
ovaries, which is derived from the coelomic  
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epithelium in fetal development. This coelomic epithelium also is 
involved in formation of the mullerian ducts, from which the fallopian 
tubes, uterus, cervix, and upper vagina develop.  
Five main histologic subtypes, which are similar to carcinoma, arise in  
the epithelial lining of the cervix, uterus, and fallopian tube: (1) serous  
(from fallopian tube), (2) endometrioid (endometrium), (3) mucinous 
(cervix), (4) clear cell (mesonephros), and (5) Brenner. 
 
Predisposing Factors: 
EOC is rare before the age of 40, increases steadily thereafter and 
peaks at the age of 65 – 75. Risk of EOC is increased in nulliparous and 
those with early menarche and late menopause which is explained by the 
theory of ‘INCESSANT OVULATION’ and by ‘GONODOTROPHIN 
THEORY’. A steady decreased risk is observed with increased parity and 
with the use of OCP. 
3 Familial Ovarian cancer syndromes have been described. 
 HBOC (Hereditary breast , Ovary cancer Syndrome) 
 Hereditary site specific ovarian cancer syndrome 
 Lynch syndrome – Type II 
 which were inherited by autosomal dominant transmission. 
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 In family with 2 first Degree relatives (mother, sister, daughter)  
with premenopausal EOC likelyhood of a female relative having an 
affected BRAC 1 or BRAC 2 gene I as 40%. 
Individuals with a mutation of BRCA 1 Gene have a 50-85%  
lifetime risk of developing breast cancer & 15 to 45% risk of developing 
EOC. 
      Individuals within a mutation of BRCA 2 have a 50-85% percent 
developing breast Cancer & 10 to 20% risk of developing EOC. 
      Mutations have been demonstrated in mismatch repair genes 
MSH1, MSH2, PMS1, PMS2. 
 
 
Assessment of risk of malignancy in EOC 
 
i. Fixed or irregular consistency on Pelvic Examination. 
ii. Solid or papillary projections on Transvaginal Sonographey. 
iii. A serum CA 125 > 35 µ per ML. 
iv. A pulsatility Index < 1 or Resistive Index <  0.4 on color Doppler. 
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If all 4 indicators are positive in a post menopausal woman, the risk for 
malignancy is 83%.  In contrast if all indicators are negative, 100% had 
benign ovarian tumor. 
Other Risk Factors Polycystic ovary disease, diet high in saturated animal 
fats, family history – 10% cases have genetic predisposition. 
Presentation patients with ovarian cancer typically show few signs or 
symptoms until the disease is widely spread throughout the abdomen. 
Non- specific GI symptoms are common, e.g. nauses, dyspepsia  
common, e.g. nausea, dyspepsia and altered bowel habit. May be a 
sensation of pelvic 
weight or pressure. Early satiety and abdominal distension occur in 
advanced disease. 
In women of reproductive age, menstrual abnormalities are seen in 
approx. 15% of Patients. 
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Diagnosis 
Presence of advanced ovarian cancer often is suspected on clinical 
grounds but can be confirmed only pathologically by removal of the 
ovaries or, when disease is advanced, by sampling tissue or ascitic fluid. 
Ultrasound Imaging is the most useful initial investigation in a patient 
found to have a pelvic mass. This may define the morphology of the 
pelvic tumor. In addition, it can determine whether large masses are 
present in other parts of the abdomen, including in the liver. This 
technique also can be used to evaluate the kidneys for evidence of 
ureteric obstruction and to detect ascites. 
CT scan with oral and intravenous contrast can detect intra abdominal 
disease and help evaluate for pelvic sidewall disease. Some have 
suggested a role in assessing operability of the tumor. Tumor markers 
such as CA125 are not good discriminators of benign from malignant 
lesions in premenopausal women. CA125 has much better accuracy in 
prognostic outcome. 
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Patterns of spread   
    EOC most often spreads initially within the peritoneal cavity. 
Metastatic disease often is found on the peritoneal surfaces, particularly 
on the undersurface of the diaphragm, the paracolic gutters, the bladder, 
and the cul-de-sac. Other common sites are the surface of the liver, the 
mesentery and serosa of the large and small bowel, in the omentum, the 
uterus, and paraaortic and pelvic lymph nodes. Outside the peritoneal 
cavity, EOC may spread to the pleural cavity, lungs, and groin lymph 
nodes. Presence of pleural effusion does not necessarily indicate disease 
in the chest, and malignancy can be diagnosed only cytologically. 
Mucinous tumors tend to form large dominant masses, while papillary 
serous tumors have a more diffuse distribution and are more commonly 
bilateral. Endometrioid and clear-cell variants more commonly exhibit 
local invasion and retroperitoneal disease.  
 
 
 
 
Staging  
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     EOC is staged according to Federation International de 
Gynecologie et Obstetrique (FIGO) (ie, International Federation of 
Gynecology and Obstetrics) rules as follows:  
Stage I - Growth limited to the ovaries. 
¾ IA - Growth limited to 1 ovary, no ascites present containing 
malignant cells, no tumor on the external surface, capsule 
intact. 
¾ IB - Growth limited to both ovaries, no ascites present 
containing malignant cells, no tumor on the external 
surfaces, capsules intact. 
¾ IC* - Tumor either stage IA or IB, but with tumor on surface 
of 1 or both ovaries with capsule ruptured, with ascites 
present containing malignant cells, or with positive 
peritoneal washings. 
• Stage II - Growth involving 1 or both ovaries with pelvic 
extension. 
 
 
¾ IIA - Extension and/or metastases to the uterus and/or tubes. 
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¾ IIB - Extension to other pelvic tissues. 
¾ IIC* - Tumor either stage IIA or IIB, but with tumor on 
surface of 1 or both ovaries, with capsule(s) ruptured, with 
ascites present containing malignant ovaries, or with positive 
peritoneal washings. 
• Stage III - Tumor involving 1 or both ovaries with histologically 
confirmed peritoneal implants outside pelvis and/or positive 
retroperitoneal or inguinal nodes; superficial liver metastasis equals 
stage III; tumor limited to true pelvis, but with histologically 
proven malignant extension to small bowel and omentum. 
¾ IIIA - Tumor grossly limited to the true pelvis, with negative 
nodes, but with histologically confirmed microscopic 
seeding of abdominal peritoneal surfaces, or histologically 
proven extension to small bowel mesentery. 
 
¾ IIIB - Tumor of 1 or both ovaries with histologically 
confirmed implants, peritoneal metastasis of abdominal 
peritoneal surfaces, none exceeding 2 cm in diameter; nodes 
are negative.  
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¾ IIIC - Peritoneal metastasis beyond the pelvis larger than 2 
cm in diameter and/or positive retroperitoneal or inguinal 
nodes. 
• Stage IV - Growth involving 1 or both ovaries with distant 
metastases; if pleural effusion is present, positive cytology must be 
apparent to allot a case to stage IV; parenchymal liver metastasis 
qualifies as stage IV disease. 
Surgery for ovarian cancer.  
Ovarian epithelial malignancies  are staged according to the FIGO 
system. The importance of thorough surgical staging cannot be 
overemphasized, because subsequent treatment will be determined by the 
stage of  disease. 
 
 
 
Technique for surgical staging:  
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For patients where pre op evaluation suggests a probable 
malignancy , a midline or paramedian  abdominal incision  is 
recommended to allow adequate access tom the upper abdomen. 
o Aspirate ascitic fluid for cytology studies.  
o Perform peritoneal washings for cytology if ascites is not 
present.  
o Remove the ovary and ovarian tumor intact.  
o Perform diaphragmatic scraping for cytology studies.  
o Obtain peritoneal biopsy specimens.  
o Perform a subcolic omentectomy.  
o Obtain bilateral paraaortic and pelvic node samples.  
o Obtain biopsy samples of adhesions or other suspicious 
areas.  
o If the patient does not desire future fertility, perform a total 
abdominal hysterectomy and excise the opposite ovary.  
o Remove the appendix if mucinous tumor is present. 
o All visible tumor should be removed. This may require 
extensive surgery, including bowel resection, excision of 
peritoneal implants, liver resection, omentectomy, and 
splenectomy.  
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o The extent of bowel resection should depend on the role this 
plays in achieving maximal cytoreduction. 
*Fluid must have been in contact with broad surfaces of the 
peritoneum above the liver, the paracolic gutters, and the pelvis. All 
specimens may be placed in the same container with heparin and 1 U/mL 
of aspirate and sent for cytology studies.  
Early Stages EOC Risk Groups. 
Low Risk High Risk 
Stage IA or IB, Grade 1 & 2  Stage IA or IB, Grade3 
 Stage IC All Stage II 
 
 
 
 
 
 
 
PROGNOSIS 
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Epithelial stage I 76 – 93% 
Epithelial stage II 60 – 74%  
Epithelial stage III 23 – 41% 
Epithelial stage IV 11%  
 
 
 
 
 
 
 
 
 
 
 
 
 
REVIEW OF LITERATURE 
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In 1809 McDowell successfully removed a diseased ovary and the 
patient survived.  This Kentucky frontier physician did 13 “ovariotomy” 
operations.  Eight women survived the surgery.  McDowell’s initial 
experience was the first time that a diseased intra-abdominal organ was 
successfully removed and the patient lived.  Nevertheless, it took almost 
another half century before the routine removal of diseased ovaries 
became an accepted surgical practice.  The diseased ovaries removed 
were invariably thought preoperatively, to be benign.  Tate introduced the 
concept of an exploratory laparotomy in 1879 as he believed that benign 
ovarian tumors might be mistaken for ovarian cancer.  It was the dogma 
of that era that one never operated on ovarian cancer because the surgery 
did little good and it had no impact on the ultimate survival of the patient.  
By the beginning of the 1900’s surgeons were routinely operating on 
women thought to have ovarian cancer in an effort to remove the diseased 
organ. 
 
 
 
In 1935, Lynch reported a landmark paper in the management of 
ovarian cancer.  He observed that ovarian cancer appeared to be familial, 
that most of the patients alive at 5 years either had borderline malignant 
potential tumors or had well differentiated cancers of the ovary and that 
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one third of the women alive at 5 years were alive with disease.  The 
latter invariably died 7-8 years following the original diagnosis.  In 1940, 
Pemberton introduced the idea of an omentectomy as part of the initial 
management of ovarian cancer.  In 1968, Munnell reported his aggressive 
surgical approach to the management of ovarian cancer which included 
resection of the sigmoid colon when the disease apparently was confined 
to the pelvis.  However, it was Griffiths10 retrospective study that 
demonstrated that when women were operated on with advanced stage 
ovarian cancer and residual disease >1.5 cm in maximum diameter were 
left in the abdominal cavity, these patients almost invariably were dead in 
2 years.  When patients were operated on and were found to have intra-
abdominal carcinomatosis but only miliary seedings, i.e. tumor implants 
<1.5 cm in maximum diameter, in the upper abdomen, such patients had a 
5 year survival of approximately 20%.  Griffiths then demonstrated, in a 
third group of patients, when large volume disease was present in the 
upper abdomen and he was able to surgically cytoreduce the cancer  
 
 
 
such that at the end of the operation the residual disease was <1.5 
cm in maximum diameter, these patients had a prolonged survival with 
20% alive at 5 years.  It was this retrospective review by Griffiths that 
 21
established the concept of aggressive surgery followed by aggressive 
chemotherapy as the ideal way to manage advanced stage ovarian 
cancer.12 
 In non-randomized studies, Piver, etal & Dottins, etal have 
reported excellent survival rates > 90% in patients treated with 
cisplatinum  based chemotherapy.   
 
  Rubin etal. reviewed 62 patients with stage I EOC.  All 
of them underwent comprehensive surgical staging followed platinum 
based chemotherapy. 15 patients relapsed (22.4%).  No patient was 
rendered disease free after relapse.  Patients with grade 3 tumors & clear 
cell histology had a higher risk of relapse. 
 
 
 
 
 
 
 
GOG Study 
 Cisplatin versus paclitaxel versus Cisplatin   and   
paclitaxel in patients with suboptimal stage III & IV .The combination 
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therapy had a better toxicity profile. Therefore combination of cisplatin 
and paclitaxel remains preferred initial treatment option. 
 
 Randamized intergroup trial of cisplatin and paclitaxel  versus 
cisplatin cyclophosphamide in women with advanced EOC  - GOG  3 
years results :  
 Incorporating paclitaxel into 1st Line therapy improves duration 
and also improve Progression free survival and of Over all survival in 
women with incompletely resected stage III & IV EOC. 
 GI COG study : Comparing cisplatin with Intraperitoneal Chromic 
Phosphate in patient with IA, IB grade 1 & 2 & IC disease. 
Cisplatin groups had a better DFS, but OS was not significantly different 
compared with other arm. 
 
  
 
 
 
 
 
GOG trial of cisplatin cyclophosphamide for 3 cycles versus Intraperitoneal 
Chromic Phosphate in highrisk early stage DOC. 
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Relapse free rate – 77% for  chemotherapy arm. 
                                         66% for 32 p.arm. 
GOG Randomized study between 3 versus 6 cycles of paclitaxel & 
carboplatin. 
This trial is obviously testing the potential benefit of so called 
“maintenance therapy”. 
 
 
 
 
 
 
 
 
 
 
 
 
 
AIM OF STUDY 
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i. To assess treatment results in Ca ovary. 
ii. Progression free time in patients with sub-optiomal cyto-reduction 
following adjuvant chemotherapy. 
iii. To assess the need for Neo – Adjuvant Chemotherapy in advanced 
Ca ovary. 
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SUBJECTS & METHODS 
 
          A prospective anaysis of 112 patients with ovarian cancer 
who had been admitted in Institute Of Obstetrics & Gynaecology 
(IOG) Government Hospital for Women and Children  between  
 Jan-2004 and August 2005(18 months study). 
Patients who had been admitted with Ovarian Cancer at Institute of 
Obstetrics & Gynecology (IOG) Government Hospital for Women and 
Children and then registered at Medical Oncology Dept., IOG  were 
analysed. 
A thorough evaluation of history & clinical findings were done  for 
all patients.  
All patients had Complete haemogram, Liver Function Test, Renal 
Function Test, CXR, ECG. 
UltraSonoGram: Pelvis and Abdomen & Computed Tomogram 
Abdomen were used to assess the extent of the tumor, in the Pelvis & 
Abdomen especially for the presence of Peritoneal, omental deposits, 
sub- diaphragmatic deposits, Para-aortic nodes, liver and spleen 
metastasis.    
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Serum Tumor markers like CA 125 estimation was done wherever 
feasible. 
  
According to laprotomy findings, 
          Patients are classified into 3 Groups. 
i. Optimal Cyto Reduction : Residual disease <2cm in 
maximal diameter.  (GRIFFITHS Criteria ) 
ii. Sub Optimal Reduction  :   Residual disease >2cm    in 
maximal diameter.   (GRIFFITHS Criteria )  
 
iii.      Open & Close :          Only  BX from tumor and omentum  were 
taken.  
 88 patients had EOC. 
 11 of 88 patients were in Early stage.  
 77 of 88 patients were in Advanced stage.  
  64  had  Adjuvant chemotherapy after laparotomy. 
 13 had Neo- Adjuvant chemotherapy. 
           Adjuvant Chemotheraphy with  Cisplatin 75 mg. /m2 & 
Cyclophospamide 750 mg. /m2 given for a period of  3 days every three 
weekly for a period of  6 cycles.  Chemotherapy was  started within 14 
days of laprotomy. 
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Occasional patients were given Chemotherapy with Carboplatin &  
Cyclophospamide  or single agent Carboplatin. 
 
13 of 77 Patients are treated with Neo Adjuvant chemotherapy who 
presented with advanced stage ovarian cancer and were medically 
disabled, with the same dose of Chemotherapy. One patient had 
Carboplatin &  Cyclophospamide   
 
Toxicity : 
Observed we are Gastro Intestinal symptoms in the form of nausea 
and vomiting, Haematological – anemia, neutropenic fever, Neurological 
- peripheral neuropathy which were noted after 6 months of 
chemotherapy. 
 
Follow Up : 
Patients are followed-up once in 3 months with Pelvic  
Examination, USG, tumor marker (whenever feasible ) for 2 years, once 
in  six months for the  next three years & once in a year for life long.  
                                      
 
RESULTS 
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Patients with EOC admitted from Jan 2004 to Aug 2005 were 
observed. 
Table – 1 
Types of Ovarian Cancer cases  
 
Epithelial  88 77% 
Border line Epithelial cell cancer 05 4.4% 
Germcell  Tumour 09 10% 
Sexcord  Stromal  cell  Tumour 07 6% 
Others –Krukenberg 
Non- Hodgkin lymphoma   
02 
01 
2.6% 
                                                 TOTAL 112  
 
78.5% of Ovarian cancer cases admitted were Epithelial Ovarian 
Cancer. 
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Table – 2 
Age distribution for Ovarian Cancer 
 
 
Age  in  years No.of  cases Percentage 
10 - 19 6 5 
20 - 29 17 15 
30 - 39 18 15.8 
40 - 49 43 38.9 
50 - 59 19 16.8 
60 - 69 3 2.6 
70 - 79 6 5.3 
 
Median Age  : 45 yrs 
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Table – 3 
 
Age Distribution for EOC 
 
Age in years  No. of cases Percentage 
20-29 10 8.8 
30-39 14 16 
40-49 39 44.2 
50-59 16 18.2 
60-69 3 3.4 
70-79 6 6.8 
 
Median age 45 Years 
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Table - 4 
 
PARITY 
 
Parity No.of  Cases Percentage 
NULLIPAROUS 25 28% 
1-2  CHILDREN 23 26% 
>2 CHILDREN 52 56% 
 
28% of 112 patients were Nulliparous. 
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Table – 5 
Histological Types of EOC. 
 
 Total No of  EOC 88  
Serous 66 75% 
Mucinous 17 20% 
Endometriod 02 02% 
Others 03 03% 
 
66 of 88 patients treated conventionally with surgical debulking had 
Serous carcinoma. 
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Table – 6 
 
Epithelial cell tumours 88     
Early Stage     11 (12.5%) 
Advanced Stage III & IV  77 (87.5%) 
 
77 (87.5%) of 88 patients are in Advanced Stage. 
 
 
 
 
 
 
 
 
 34
 
Table - 7 
 
LAPAROTOMY RESULTS 
 
Sub Optimal Cyto 
reduction 
52 (81.25%) 
Open &Close 12 (18.75%) 
Total  64  
                                      
(Residual disease > 2cm in in maximal diameter) 
All patients had Total Abdominal Hysterectomy and Bilateral Salpingo 
Oophorectomy,partial omentectomy. 
 
 
Table – 8 
Treatment  given : 
 
Adjuvant chemotherapy 64 
Neo- Adjuvant chemotherapy 13 
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Table 9 
 
Adjuvant Chemotherapy Schedule in Advanced EOC. 
 
Drugs Dose Interval Period of 
Treatment 
No : 
Cisplatin 
& 
Cyclophospamide 
75mg/m2 
750 
mg/m2 
Every 3 
weeks  
6 cycles 63 
Carboplatin 
& 
Cyclophospamide 
 
AUC 5-
6 
75mg/m2 
 
Every 4 
weeks 
6 cycles 1 
 
 
63 patients had combination chemotherapy with Cisplatin 75 mg/m2and 
Cyclophosmamide 750 mg/m2 every 3 weeks for a total period of 6 cycles. 
1 patient  had single dose Carbo platin in Adjuvant Chemotherapy. 
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Table -10 
 
Neo - Adjuvant Chemotherapy Schedule in Advanced EOC. 
 
Drugs Dose Interval Period of 
Treatment No : 
Cisplatin 
& 
Cyclophospamide 
75mg/m2 
750 
mg/m2 
Every 3 
weeks  
3 cycles 12 
Carboplatin AUC 5-6 
Every 4 
weeks 
3 cycles 1 
 
 
12 patients had combination Chemotherapy Cis platin 75 mg/m2 with 
Cyclophosmamide 750 mg/m2 every 3 weeks for a total period of 3 
cycles.1 patient  had single dose Carbo platin in Neo Adjuvant 
Chemotherapy. 
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Table- 11 
 
 
 Adjuvant 
Chemotherapy  
 
Neo-Adjuvant 
Chemotherapy  
 
Lost Follow-up 18 6 
Death 2 1 
 
 
                                                       
Table – 12 
 
Toxicity 
 
Gastro - Intestinal 80% 
Haematological  20% 
Neurotoxicity 20% 
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Table – 13 
 Median Time to Progression in Patients after  Adjuvant 
Chemotherapy 
 
 
 
 Table – 14 
 
 
 
Suboptimal –reduction 9 months 
Open & Close 6 months 
Median Time to Progression in Patients after Neo- Adjuvant 
Chemotherapy  
9 months 
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Table - 15 
Progression free Survival following  
 >12months            < 12 months 
Adjuvant 
Chemotherapy 
After Suboptimal - 
reduction 
11 13 
Neo Adjuvant 
Chemotherapy 
4 0 
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RESULTS 
 
The high mortality from ovarian cancer reflects a lack of an effective 
screening procedure. The 5 year survival for the majority of patients with 
this disease (FIGO stage III & IV) is approximately 20%.Although 
dramatic improvements  in treatment have led to prolonged disease free 
survival for the overwhelming  majority of these women with stage III 
&IV disease, intense cytoreductive surgery followed by chemotherapy is 
only palliative treatment. 
78.5% ovarian cancer belong to the malignant EOC (Refer Table—1) 
which correlates well with the statistics of Jemal A.etal  & Young a study 
on cancer statistics which states that 90 % of ovarian tumors belong to 
EOC. The median age of ovarian cancer is 45 years (Refer Table-2) 
which is 1-2 decade less than the age observed by Truong LD et all (55-
65 years). The median age of EOC is 45 years(Refer Table3) which is one 
decade less than study observed by Prcorelli S. Odicini F, the peak 
incidence  of EOC is at 56 to 60 years of age.  
      EOC has been associated with increase in parity > 2 children 
i.e.,(57%) (Refer Table 4) which is in contrast with the study of    
Negrietal in which nulliparous women has the highest incidence-(a study 
of reproductive factor and risk of EOC) which states that ovarian cancer 
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has been associated with low parity and infertility. Early menarche and 
late menopause increase the risk of ovarian cancer. (Franceschi S1 et al ). 
The suppression of ovulation may be an important factor. 
   66 of 88 patients treated conventionally with surgical debulking had 
Serous  Ca, (Refer Table 5) which correlates well with the study of  Scully 
R, YoungR H in which 75 % of EOC are of Serous histologic  type. Less 
common are mucinous (20 %) endometroid (2%),  others (3%). 
         According to Laparotomy results 11 patients of 88 were Early stage. 64 of 
88 patients were in Advanced stage (Refer Table 6).64 patients of 88 had 
Sub optimal cyto reduction in our Institute.including 12 cases of Open & 
Close cyto reduction.(Refer Table 7) 
     11 patients in Early stage had no recurrence till the last day of follow 
up, to whom no chemotherapy was given. The primary surgical treatment 
they had undergone was total abdominal hysterectomy and bilateral 
salpingo oopherectomy. In certain circumstances, an unilateral 
oopherectomy was performed. 
 
 
Adjuvant Chemotherapy 
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63 of 77 patients had combination chemotherapy with cisplatin and 
cyclophospamide (Refer Table 8) 
44 patients had completed combination Chemotherapy of       Cis 
platin 75 mg/m2 with Cyclophosmamide 750 mg/m2 every 3 weeks  for a 
total period of 6 cycles.  1 patient  had single dose Carbo platin in 
Adjuvant Chemotherapy.(Refer Table 9).  
 DISEASE FREE SURVIVAL  
 13 patients had DFS until 12 months. 
 11 patients had DES > 12 months 
  18 patients lost follow up 
  2 deaths occurred 
 PROGRESSION FREE SURVIVAL 
  11 patients are living more than 12 months without any  
  recurrence  
  13 patients are living 6 – 12 months without any   
  recurrence.  (Refer Table 15) 
 
 
 
Neo Adjuvant Chemotherapy 
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12 of 13  patients had combination Chemotherapy every 3 Cis platin 75 
mg/m2 with Cyclophosmamide 750 mg/m2 every 3 weeks over 3 cycles1 
patient  had single dose Carbo platin in Neo Adjuvant Chemotherapy. 
(Refer Table 10) 
 
5 patients lost follow-up and one patient died during Neo Adjuvant 
Chemotherapy(Refer Table 11) 
In Neo Adjuvant Chemotherapy 3out of 13 patients had 
recurrences with progressive disease.  4 out of 13 patients had 
progression free survival.(Ref Table : 15) 
Progression Free survival period for New Adjuvant treatment is 14 
months when compared with conventionally treated women is 9 months. 
(Ref  Table : 15) 
 
 
 
 
 
 
 
Medium Time to progression for disease  for 13 woman who 
received Neo Adjuvant Chemotherapy is 9 months versus 9 months for 
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64 patients who had suboptimal cytoreduction followed with Adjuvant 
Chemotherapy 
(Ref  Table : 13 & 14) 
 
The toxicity symptoms noted were in the form of Gastro Intestinal-
nausea vomiting Dyspepsia, Haematological – Anemia, Neutropenia, 
Neurological – peripheral neuropathy which were noted after 6 months of 
Chemotherapy (Ref  Table : 12) 
Patients after Chemotherapy were evaluated with USG/CT/TumorMarker 
(wherever feasible)to help to assess whether the patient had regression of 
disease or persistent disease.  
  
 
 
 
 
 
 
     It is our intention to proceed with a prospective randomized study 
comparing Neo adjuvant cisplatinum and Cycliphosmamide 
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chemotherapy to conventional cyto reductive  surgery followed by the 
same chemotherapy. Inclusive criteria of eligibility of this study being 
that the women must have cytologic evidence of a malignancy with an 
epithelial cancer who had conventional cyto reductive surgery followed 
by Adjuvant chemotherapy. Since our institution is funded by 
Government cost/benefit analysis  of surgery and chemotherapy is not 
performed. 
                                             
 
 
 
 
 
 
 
DISCUSSION 
 46
     Treatment of ovarian cancer was undertaken  after consideration of 
many factors, including the extent of disease spread, symptoms,and 
patients’ wishes and fitness to undergo treatment. 
Surgery 
       Surgery was the initial treatment of choice,provided patients are 
medically fit. Patients who were not fit for surgery was given 
chemotherapy and considered for surgery later. The aim of surgery was to 
confirm the diagnosis, define the extent of disease and resect all visible 
tumor. The role of cytoreduction was demonstrated by Griffiths in 1975 
and has been confirmed by others. 
11 patients in Early stage had no recurrence till the last day of follow up 
to whom no chemotherapy was given. The primary surgical treatment 
they had undergone was total abdominal hysterectomy and bilateral 
salpingo oopherectomy. In certain circumstances, an unilateral 
oopherectomy was performed 
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The role of cyto reductive surgery is based on retrospective reviews.The 
best candidates for cytoreductive surgery are those with limited slow 
growing tumors. Cyto reduction often improves function & quality of life 
when performed as a palliative treatment to remove a bulky symptomatic 
tumor. The volume reduction also diminishes the metabolic demands 
made on the host by the tumor. 
 
Cytoreductive surgery is not without potential hazards. Although surgical 
and anesthetic techniques have improved, the inherent risks of any 
surgical procedure must be considered in the overall assessment of the 
patient. Despite careful attention to detail, there is always a potential risk 
of physical dissemination of disease. Furthermore, surgery-induced stress 
causes a transient immune suppression that could, in theory, temporarily 
enhance tumor growth or spread. The time spent first in planning surgery 
and then in recovering from surgery could delay other potentially 
beneficial treatments. 
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There was found to be partial Omentectomy and there was no 
Pelvic/Para-aortic clearance in some cases (Sub optimal reduction in 
advanced stages of EOC in our study.In addition, quality of life is likely 
to be siginificantly enhanced by removal of bulky tumor masses from the 
pelvis and abdomen(13). 
 
An Analysis of the retrospective data available suggests that these  
operations are feasible  for 70% to 90 % of patients when performed by 
Gynecologic Oncologists The conventional management of EOC is 
aggressive cyto reductive surgery followed by Platinum-Taxane 
combination chemotherapy. In our Institution we have used  Cisplatin 
&Cyclophospamide.The role of cyto reductive surgery is based on 
retrospective reviews.The best candidates for cytoreductive surgery are 
those with limited slow growing tumors. Cyto reduction often improves 
function & quality of life when performed as a palliative treatment to 
remove a bulky symptomatic tumor.The volume reduction also 
diminishes the metabolic demands made on the host by the tumor. 
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The conventional management of EOC is aggressive cyto rective surgery 
followed by Platinum-Taxane combination chemotherapy. In our 
Institution we have treated with Cisplatin &Cyclophospamide.  
 
Patients are treated with Neo- Adjuvant chemotherapy who presented 
with advanced stage ovarian cancer and were medically disabled.3-5  Over 
the ensuing decade a reasonable experience was obtained suggesting that 
patients who were medically unable to tolerate aggressive cytoreductive 
surgery at the time of their initial presentation, but who received 
chemotherapy and then were able to undergo cytoreductive surgery, had a 
survival that was quite similar to those patients who initially had large 
volume disease present in the upper abdomen or Stage IV disease.  A 
decade later, neoadjuvant chemotherapy followed by aggressive surgery 
was introduced for patients who were not medically compromised but 
who, by CT scan criteria, appeared to have disease that was not surgically 
cytoreducible.  Basically, patients with disease >2 cm in diameter in the 
upper abdomen that involved coating the diaphragm and was confluence 
with implants in the liver serosa, omentum replaced by tumor with the 
tumor in the omentum reaching the hilum of the spleen, porta hepatis 
metastases, enlarged (>2 cm) suprarenal para-aortic lymph nodes and 
disease in the thorax were indications to recommend neoadjuvant 
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chemotherapy as these preoperative CT findings were usually associated 
with extensive upper abdominal metastases that could not be optimally 
cytoreduced.  Our criteria for selecting patients for neoadjuvant 
chemotherapy also required cytology or histology specimens consistent 
with ovarian cancer to be present before chemotherapy is initiated.   
 
Neoadjuvant chemotherapy for the treatment of advanced stage ovarian 
cancer as employed in this presentation means that the chemotherapy is 
administered before any surgery is performed.  Cytologic material or 
biopsies can be obtained using diagnostic imaging to direct the biopsy.  
Patients who receive neoadjuvant chemotherapy are ultimately 
recommended to undergo standard cytoreductive surgery.  Neoadjuvant 
chemotherapy must be distinguished from interval debulking surgery.  
The latter is performed when suboptimal cytoreduction is done as the 
initial operation.  In general patients receive 3 cycles of chemotherapy 
following suboptimal surgical cytoreduction then undergo interval 
debulking surgery.  Data has been presented suggesting that those 
patients who have been suboptimally cytoreduced, have 3 cycles of 
platinum-based chemotherapy and then are optimally cytoreduced, do 
better than those patients who do not undergo interval cytoreductive 
surgery.14  However, data suggests that interval cytoreduction does not 
improve the results of initial suboptimal cytoreduction.  Patients who are 
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being operated for ovarian cancer should be operated by physicians 
trained to do aggressive cytoreductive surgery.  Conventional treatment is 
aggressive cytoreductive surgery followed by aggressive chemotherapy.  
Neoadjuvant chemotherapy for the management of ovarian cancer 
reverses the treatment techniques used in conventional treatment. 
 
The major concern about neoadjuvant chemotherapy in the management 
in advanced stage ovarian cancer has been an issue of survival.  There are 
now multiple studies which suggest that the survival of patients treated 
with neoadjuvant chemotherapy is similar to that of patients who undergo 
conventional treatment There appears to be no compromise in overall 
survival.  However, to achieve survival comparable to that of women who 
undergo conventional treatment, it is necessary that optimal cytoreductive 
surgery is performed following completion of the neoadjuvant 
chemotherapy.  If one delays the time from completing the chemotherapy 
to the time of performing the surgery that resistant disease develops that 
is not responsive to conventional chemotherapy. 
 
Reports from Yale-New Haven Hospital and many other sites would 
strongly suggest that neoadjuvant chemotherapy plays a strong role in 
women with advanced stage ovarian cancer that is not surgically 
cytoreducible. Other institutions are now using laparoscopy to assess 
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surgical cytoreducibility. One report suggests that all patients with Stage 
III disease, not just those that are non-cytoreducible, may be treated with 
neoadjuvant chemotherapy followed by surgery without compromising 
their survival.  Currently reports on neoadjuvant chemotherapy for the 
treatment of advanced stage ovarian cancer are either retrospective or 
limited in patient numbers.  The European Organization for the Research 
and Treatment of Cancer (EORTC) study is now randomizing 742 
women between neoadjuvant chemotherapy (platinum and taxane) for 3 
cycles followed by aggressive cytoreductive surgery followed by 3 more 
cycles of chemotherapy vs. conventional treatment, i.e. aggressive 
cytoreduction followed by 6 cycle of the combination of platinum and 
paclitaxel.  The results of that trial will be extremely helpful in sorting out 
a role for neoadjuvant chemotherapy in the management of advanced 
stage ovarian cancer. 
 
SUMMARY 
 
112 patients who had been admitted with Ovarian Cancer at 
Institute of Obstetrics & Gynecology (IOG) Government Hospital for 
Women and Children and then registered at Medical Oncology Dept., 
IOG  were analysed. 
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88 of 112 patients had Epithelial Ovarian Cancer. 
11 of 88 patients were in Early stage had no recurrence till the  last 
day of  followed up, to whom no chemotherapy was given  and 
 were follow up. 
77  of 88 patients were in Advanced stage . 
 64 of 77 had  Adjuvant chemotherapy with  Cisplatin 75 mg. /m2  
 & Cyclophospamide 750 mg. /m2 given over 3 days every three 
weekly for a period of 6 cycles.  Chemotherapy was  started within 
14 days of   laprotomy. 
 
 
                     
  13 of 77 patients are treated with Neo Adjuvant chemotherapy with 
the same dose of chemotherapy for a period of 3 cycles, were followed 
up. 
Median time to progression for disease  for 13 women who 
received Neo Adjuvant Chemotherapy is 9 months versus 9 months for 
64 patients who had suboptimal cytoreduction followed with Adjuvant 
Chemotherapy 
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 Progression Free survival period for Neo Adjuvant treatment is 14 
months when compared with conventionally treated women is  
9 months. 
 
Neo adjuvant chemotherapy  can be considered to improve the 
quality of life, surgical results and subsequently the disease progression 
period. 
 
 
 
 
 
 
 
CONCLUSION 
 
¾ Advanced EOC Contributes 87.5% of Ovarian Cancer.  
 
¾ Median time to progression is 9 months following Sub optimal 
surgery and Adjuvant Chemotherapy. 
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¾ Progression Free survival period for Neo-Adjuvant treatment is 14 
months.  when compared with conventionally treated women is 9 
months. 
 
¾ Neo adjuvant chemotherapy  can be considered to improve the 
quality of life, surgical results and subsequently the disease 
progression period. 
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MASTER CHART 
 
ADJUVANT CHEMO THERAPY IN OVARIAN EPITHELIAL 
TUMOR 
  
           
S.No AGE Parity ClinicalFeatures HPE/FNAC Stage            USG CXR 
Neo 
Adj 
Surgery 
1 4 1 1,2 1a III 2 1  1,2  
2 5 3 1,2,3 1a  bt Ia 2 1  1  
3 8 3 1,3 5 IV 1,3 1 1 -  
4 6 2 1,2 4 IIIc 1,3 1 1 -  
5 5 2 1,2 1 IIIc 2 1  1,2  
6 4 3 1,2,3 3  gct IIIc 2,4 1  1,2  
7 7 3 1,2 1 IIIc 1,2 2  1  
8 6 2 1,2,3 1 IIIc 2 1  1,2  
9 5 2 1,2 1 IV 2 1  4  
10 6 3 1,3 1 IV 2 1  1  
11 2 4 1,3 3  gct Ia 2 1  4  
12 6 3 3 5 IIIc 1,2 1  4,2  
13 3 1 1,3 1 I 1,2 1  1  
14 5 3 1,3 1 III 1,2 1  1,2  
15 8 3 ,4 5 IIIc 2 1  1  
16 5 3 1,2 1 III 1,2 1  1  
17 5 1 1,3 1 I 1,2 1  1,2  
18 3 1 1,2,3 3 gct III 2 1  4  
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19 4 3 1,2,3,4 4 I 2 1  1,2  
20 6 1 1,2,3 1 I 1,2 1  1,2  
21 2 4 1,2,3 5 IV 2 1  2,4  
22 4 2 1,2,3 1 III 2 1  1  
23 6 3 1,2,3 1 IV 1,2 1  4  
24 7 3 1,2,4 1 IV 2,4 1 1 -  
25 6 1 1,2 1 IIIc 2,4 1  1,2  
26 4 3 1,4 3 Ia 2 1  1  
27 3 3 1,2,3 2 I 2 1  1,2  
28 5 1 1,2,3 3 IV 1,2 1  -  
29 6 2 1,3 1 IIIc 2,3 1 1 -  
30 5 2 1,2,3 1b IIIc 2,3 1  1,2  
31 6 3 1,2,3 4 III 1,2 1  -  
32 2 4 1,2 1b Ia 2 1  1,2  
33 7 1 1,2,3 4 IV 1,2 1 1 -  
34 2 4 1,2,3 3 Ivc 2,4 2  1,2  
35 8 3 1,2,3, 1c Ia 2 1  1,2  
36 6 1 1,2,3 4 IIIc 2 1  1,2  
37 4 2 1,2,3 1 IIIc 2 1  1,2  
38 5 1 3,4 4 - 2 1  1,2  
39 8 3 1,2,3 1a Ia 2 1  1,2  
40 3 4 4 3 I 2 1  4  
41 5 1 4 5 I 2 1  1,2  
42 6 2 1,2,3 4 IV 1,2,3 1 1 -  
43 7 1 1,2,3 4 IV 1,2 1 1 -  
44 6 1 2,3 1 IIIc 1,2 1  -  
45 4 3 1,2,3 4 IV 1,2 1 2 -  
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46 6 3 1,2,3 5 IV 1,2,3 1 1 -  
47 7 3 1,2,3 1a IIIa 2 1  1  
48 5 3 1,2,3 1b IIIb 2 1  1  
49 4 3 4 4 Ia 2 1  4  
50 4 1 1,2,3 4 IIIc 1,2 1 1 -  
51 5 3 1,2,3 1b IIIc 1,2 1  1,2  
52 3 2 1,2,3 1b IIIc 2 1  1  
53 6 3 1,2 1b Ic 2 1  1  
54 3 4 1,2,3 1c Ic 2 1  4  
55 5 3 1  I 1 1  _  
56 6 1 1,2,3 1b IV 1 1  _  
57 5 3 1,2,3 5 IIIc 2 1  4  
58 6 2 1,2,3 1 IIIc 1,2 1  1,2  
59 4 2 1,2,3 4 IIIc 2 1  1  
60 5 2 1,2,3 1a IV 1,2 1 2 _  
61 8 3 1,2,3 1a IIIc 2 1  1,2  
62 3 2 1,2,3 1 IIIc 1,2 1  1,2  
63 3 2 1,2,3 2 Ia 2 1  4  
64 6 3 1,2,3 1 IIIc 2 1  1,2  
65 5 1 2,3 4 IV 2 1  1,2  
66 5 3 1,2,3 4 III 1,2 1  1,2  
67 5 3 1,2,3 1a IV 2 1  4  
68 6 2 1,2,3 1 III 2 1  1  
69 6 3 1,2,3 1 IIIc 1,2 1  4  
70 2 4 3,4 3 IV 2 1  4  
71 3 2 1 3 IIIc 2 1  4  
72 4 2 1,2,3 1a IV 1,2 1  4  
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73 5 1 1,2,3 1 III 2 1  1,2  
74 6 3 1,2,3 1b IIIc 1,2,4 1  1,2  
75 5 2 1,2,3 1a Ic 2 1  1,2  
76 6 1 1,2,3 1b IIIc 1,2 2  1  
77 5 3 1,2,3 1a IIIc 1,2 1  4  
78 5 3 1,4 4 I 2 1  1  
79 7 3 1,2,3 1 IIIc 1,2 1  1,2  
80 5 2 1,2,3 1b Ia 2 1  1  
81 5 1 1,2,3 1a IV 1,2 2  4  
82 4 2 1 2  bt Ia 2 1  4  
83 5 2 1,2,3 1 IIIc 2 1  4  
84 8 2 4 1 Ia 2 1  1  
85 4 2 1,2,3 1 IIIc 2 1  1  
86 6 2 1,2,3 4 IV 1,2 1  4  
87 3 3 1,2,3 3 I 2 1  1,2  
88 3 4 1,2,3 1b Ia 2 1  4  
89 4 3 1,2,3 1  bt IIIc 1,2 1  4  
90 6 2 2,3 1 III 2 1  1,2  
91 2 4 1,2,3 3 III 1,2,3 1  _  
92 5 1 1,2,3 1c Ic 2 1  1,2  
93 5 2 1,2 1b IIIc 2 1  1,2  
94 8 2 1,2,3 1 III 1,2 1  4  
95 3 2 1,2,3 3 IIIa 2 1  1,2  
96 5 2 1,2,3 4 III 1,2 1  _  
97 5 3 1,2,3 1a IV 1,2 1  1  
98 5 3 1,2,3 1a III 1,2 1  4  
99 5 3 1,2,3 1b IIIc 2 1  1  
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100 5 1 1,2,3 1b Ia 2 1  1  
101 5 3 1,2,3 1 IIIc 1,2 1  4  
102 4 3 1 1b   bt Ia 2 1  1  
103 5 1 1,2,3 1a III 2 1  1,2  
104 5 3 2,3 1b IIIc 1,2 1  1,2  
105 3 1 1,2,3 1a Ia 2 1  4  
106 3 2 1,2,3 5 IV 1,2 2  1,2  
107 6 2 1,2,3 4 IV 1,2 1 1 _  
108 5 2 1,2,3 1 III 1 1  4  
109 6 1 1,2,3 1b III 2 1  1  
110 2 4 1,2,3 4 IV 1,2,3,4 1  4  
111 7 3 1,2,3 1 III 1,2 1  4  
112 6 1 1,2,3 1 IIIc 2 1 1   
 
 
 
 
S.no 
 
 
 
 
Laprotomy-Results 
 
 
 
 
Adj.Chemo 
 
 
 
 
Toxicity 
 
 
 
 
DFS 
 
 
 
 
 
DOR-
DOF 
1 3 2 1,2 2 3 
2 2 0 1,2 2 2 
3 - - 1,2 2 2 
4 - - 1 2 1 
5 3 1 2 2 3 
6 3 1 1 1 1 
7 3 1 1 1 2 
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8 3 1 1,2 2 2 
9 4 2 1,2,3 1 3 
10 3 1 2,3 3 3 
11 2 - 1 3 3 
12 3 - 2 1 1 
13 3 2 1,3 1 1 
14 3 2 1,2 1 2 
15 3 - 1,2 2 2 
16 3 1 1,2 1 1 
17 3 1 1,3 1 1 
18 3 2 1,2,3 5 - 
19 3 - 1 3 3 
20 3 - 1 5 - 
21 3 1 1,2 1 1 
22 3 1 2 2 3 
23 4 1 1 1 3 
24 - - 3 2 3 
25 2 1 1 2 3 
26 2 - 1,2 2 2 
27 3 - 1,2 - - 
28 - - 1,2 1 - 
29 - - 1,2 3 - 
30 3 - 1,2 3 - 
31 - - 1,3 - - 
32 2 1 1,2 3 3 
33 - - 1 - - 
34 3 2 3 2 2 
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35 3 - ,1 3 3 
36 3 2 1 3 3 
37 3 1 2 2 2 
38 2 - 1 3 3 
39 2 1 1,2 3 3 
40 2 - 1,2 2 2 
41 2 2 1,2 2 2 
42 - - 1,2 1 1 
43 - - 1,2 - - 
44 - - 1,2 5 - 
45 - - 1,3 5 - 
46 - - 2 1 1 
47 3 1 1 2 2 
48 3 1 1 1 5 
49 2 - 2 5 5 
50 - - 1,2 5 5 
51 3 1 1,3 2 2 
52 3 - 1 5 5 
53 3 1 2 2 2 
54 3 1 1,2 2 2 
55 - - 1 2 2 
56 - - 1,2 5 5 
57 3 1 3 2 2 
58 3 2 1,2 2 2 
59 3 1 1 2 2 
60 - - 1,2 5 5 
61 3 1 1,3 2 2 
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62 3 1 1 2 2 
63 2 - 1 2 2 
64 3 1 ,1,2 2 2 
65 3 2 1,2 5 5 
66 3 1 1,3 2 2 
67 4 1 1, 2 2 
68 3 2 1 5 5 
69 4 2 1 5 5 
70 3 1 1.2 2 2 
71 3 - 1.2 5 5 
72 3 1 1,3 2 2 
73 3 1 1,2 - 2 
74 3 - 1,2 5 5 
75 3 1 1,2 1 1 
76 3 1 1 - 1 
77 4 1 1 - 1 
78 2 1 2 - 1 
79 3 1 2 - 1 
80 2 - 3 5 5 
81 4 1 1,2 - 1 
82 2 - 2,3 - 1 
83 4 1 1,2 1 1 
84 2 - 1,3 - 1 
85 3 2 1,2 1 1 
86 4 2 1,2 5 5 
87 2 - 1 - - 
88 2 - 1 1 1 
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89 4 2 2 1 1 
90 3 2 2 1 - 
91 - - 1,2 - - 
92 3 2 1,2 1 1 
93 3 2 1,3 1 1 
94 3 - 1,2 5 5 
95 3 1 2,3 1 1 
96 - - 1,2 5 5 
97 3 2 1,2 - - 
98 4 2 1,3 - - 
99 3 2 1,2 - - 
100 2 - 1 - - 
101 3 2 1 - - 
102 2 - 1,2 - - 
103 3 2 2,3 - - 
104 3 2 1,2 - - 
105 3 - 1,2 - - 
106 3 - 1,2 - - 
107 - - 1,2 - - 
108 4 1 1,2 - - 
109 3 2 2,3 2 2 
110 4 - 1 1 1 
111 3 2 1 - - 
112 - - 1,3 2 2 
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Age in 
years 
Parity Clinical - 
Features 
 
 
HPE 
1 – 9  (1) Nulliparous 
(1)  
Abd.. mass with 
distension (1) 
I  (1) Epithelial  
1A - Serous 
10 – 19  (2) 1 -2 Children  
(2) 
Loss of appetite 
and loss of wt (2) 
II (2)  1B Mucinous 
20 – 29 (3) > Children (3) Pain abdomen (3) III (3) 1C 
Endometriod 
30 – 39 (4)   Gynaec.complaints 
(4) 
IV (4) B Border Line 
(2) 
40 – 49 (5)    Germcell 
Tumor (3) 
50 – 59 (6)    Stromalcell 
Tumor (4) 
60  - 69 (7)     Others (5) 
70 – 79 (8)      
 
 
 
USG CXR Surgery Laprotomy - 
Results 
DFS 
Ascites (1)  NAD  (1) TAH with BSO 
(1) 
Optimal (1) < 6 months (1)
Solid & Cystic 
(2)  
Other Changes 
(2)  
Omental Bx & 
Omentectomy 
Sup Optimal 
(2) 
6 – 12 months 
(2) 
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(2)  
Liver mets (3)   Peritoneal Bx  
(3) 
Gross residual 
(3)  
> 12 months 
(3) 
Hydronephrosis 
(4)  
 Others (4) 
(Laprotomy & 
Open & Close) 
Open & Close 
(4) 
On going 
Chemo (4) 
Lymph Nodes 
(5)  
   Lost Follow-
up (5) 
 
 
 
Toxicity 
G . I System  (1) 
Neuro Toxicity  (2) 
Haematological (3) 
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